The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarq: A novel approach to automated HER2-analysis of circulating tumor cells (CTCs).
Aurelia Pestka
No relevant relationships to disclose
Thomas W. P. Friedl
No relevant relationships to disclose
Leonie Majunke
No relevant relationships to disclose
Bernadette Jaeger
No relevant relationships to disclose
Ulrich Andergassen
No relevant relationships to disclose
Julia Katharina Neugebauer
No relevant relationships to disclose
Julia Kathrin Jueckstock
No relevant relationships to disclose
Jan Keij
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Research Funding - Veridex
Klaus Friese
No relevant relationships to disclose
Tanja N. Fehm
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Volkmar Mueller
No relevant relationships to disclose
Wolfgang Janni
Consultant or Advisory Role - Veridex
Research Funding - Veridex
Expert Testimony - Veridex
Brigitte Kathrin Rack
Research Funding - Veridex